Area soci

229 - Livelli sierici di COMP in pazienti affetti da artrite reumatoide prima e dopo trattamento con infliximab: performance analitiche e correlazioni cliniche

Autore/i: M. Tampoia, A. Zucano, V. Brescia, A. Fontana, E. Scioscia, G. Lapadula, N. Pansini

Rivista: RIMeL - IJLaM, Vol. 2, N. 3, 2006 (MAF Servizi srl ed.)

Background. Cartilage oligomeric matrix protein
(COMP) is a biomarker for the cartilage turnover and
is described as a valuable parameter for the assessment
of therapy response in patients with rheumatoid arthritis
(RA). This study evaluated the analytical performances
and clinical correlations of an automated enzyme
immunoassay for the detection of COMP
(COMPR ELISA; AnaMar Medical AB, Lund, Sweden).
Methods. Commercial controls and serum pool were
used to evaluation of method precision and accuracy
in accordance with the description in the NCCLS guideline
EP15-A2. Twenty-eight patients with established
RA were studied during a 6-month period from initiation
of treatment with infliximab. COMP levels were
correlated with clinical evaluation and laboratory tests
(VES, C reactive protein) and compared before and
after treatment.
Results. The total imprecision (CV% within-laboratory)
was 3.27%-5.50% for concentrations ranging between
7.09 and 14.69 U/L. The test was linear for concentrations
ranging between 4 and 32 U/L. COMP levels
decreased in ACR responders patients, remained unchanged
or increased in ACR non responders. There
was no significant correlation between COMP levels
and laboratory test evaluated.
Conclusions. The COMP assay we examined on a fully
automated system showed a good analytical performances
(precision and linearity) and can provide useful
data for evaluating tissue effects of novel treatment in

Articolo in formato PDF

Torna al numero corrente